Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation

Phase 3CompletedNCT00623701

Allergopharma GmbH & Co. KG126 enrolled

Overview

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

126

Conditions

Allergy Rhinitis Conjunctivitis

Interventions

Allerslit forteBIOLOGICAL

sublingual placebo preparation, daily

Allerslit forteBIOLOGICAL

Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Allergic rhinoconjunctivitis attributable to grass pollen * Positive SPT * Positive EAST * Positive provocation Test Exclusion Criteria: * Serious chronic disease * other perennial allergies

Locations (1)

Prof. Kristian Reich, MD

Hamburg, Germany

Outcomes

Primary Outcomes

Symptom and Medication Score

Time frame: Grass pollen season 2009

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.